Close Menu

Regulus

NEW YORK (GenomeWeb) — Regulus Therapeutics this week released interim results from an ongoing Phase I study of its microRNA-targeting hepatitis C therapy RG-101, which showed that a single subcutaneous dose of the drug could trigger an average 4.1-log reduction in viral loads in patients — a num

NEW YORK (GenomeWeb) – Regulus Therapeutics announced last week that it has initiated a natural history of disease study, called ATHENA, in patients with Alport syndrome.

Title: Nucleic Acid Microparticles for Pulmonary Delivery
Patent Number: 8,808,747
Filed: April 17, 2008

NEW YORK (GenomeWeb) – Officials from Regulus Therapeutics this week provided updates for the company's two lead drug candidates, stating that a Phase I study of its hepatitis C treatment RG-101 is set to yield key data in the next few months, while the preclinical Alport syndrome therapy RG-012

NEW YORK (GenomeWeb) – Regulus Therapeutics today announced a new collaborative agreement with Biogen Idec to identify microRNAs for multiple sclerosis.

NEW YORK (GenomeWeb) – New data published this month by researchers from Regulus Therapeutics and academic collaborators show that long-term therapeutic silencing of microRNA-33 could result in a number of deleterious effects in mice including fatty liver and elevated triglyceride levels.

NEW YORK (GenomeWeb) – Regulus Therapeutics this week announced that the US Food and Drug Administration has granted orphan drug status to the company's preclinical Alport syndrome therapy RG-012.

NEW YORK (GenomeWeb) – Microlin Bio is pushing ahead with its bid to go public on the Nasdaq, disclosing last week that it now expects to float roughly 4.3 million shares for between $6.50 and $7.50 apiece, which would raise as much as $32.3 million for the microRNA therapeutics and diagnostics s

Regulus Therapeutics has appointed Paul Grint as its chief medical officer.

NEW YORK (GenomeWeb) – As its recently established microRNA biomarker division makes gains with both partnered and in-house programs, Regulus Therapeutics is weighing the possibility of spinning off the unit as a standalone company that would develop and market clinical assays based on the small,

Pages

New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.

A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.

Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.

In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.